CANADABIS CAPITAL INC (CANB.CA) Fundamental Analysis & Valuation

TSX-V:CANB • CA13530Q1046

0.02 CAD
0 (0%)
Last: Mar 12, 2026, 07:00 PM

This CANB.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, CANB scores 2 out of 10 in our fundamental rating. CANB was compared to 34 industry peers in the Pharmaceuticals industry. While CANB is still in line with the averages on profitability rating, there are concerns on its financial health. CANB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. CANB.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CANB has reported negative net income.
  • In the past year CANB has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: CANB reported negative net income in multiple years.
  • CANB had negative operating cash flow in 4 of the past 5 years.
CANB.CA Yearly Net Income VS EBIT VS OCF VS FCFCANB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

1.2 Ratios

  • The Return On Assets of CANB (-5.26%) is better than 61.76% of its industry peers.
  • CANB's Return On Equity of -16.69% is in line compared to the rest of the industry. CANB outperforms 55.88% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 1.62%, CANB is in the better half of the industry, outperforming 67.65% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CANB is above the industry average of 8.22%.
  • The 3 year average ROIC (12.44%) for CANB is well above the current ROIC(1.62%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA -5.26%
ROE -16.69%
ROIC 1.62%
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
CANB.CA Yearly ROA, ROE, ROICCANB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 -200 -300

1.3 Margins

  • The Operating Margin of CANB (1.90%) is better than 64.71% of its industry peers.
  • CANB's Operating Margin has declined in the last couple of years.
  • With a decent Gross Margin value of 45.50%, CANB is doing good in the industry, outperforming 64.71% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CANB has grown nicely.
Industry RankSector Rank
OM 1.9%
PM (TTM) N/A
GM 45.5%
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
CANB.CA Yearly Profit, Operating, Gross MarginsCANB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

1

2. CANB.CA Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CANB is creating value.
  • The number of shares outstanding for CANB remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for CANB has been increased compared to 5 years ago.
  • Compared to 1 year ago, CANB has a worse debt to assets ratio.
CANB.CA Yearly Shares OutstandingCANB.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
CANB.CA Yearly Total Debt VS Total AssetsCANB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • Based on the Altman-Z score of 0.17, we must say that CANB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.17, CANB is in line with its industry, outperforming 58.82% of the companies in the same industry.
  • A Debt/Equity ratio of 1.00 is on the high side and indicates that CANB has dependencies on debt financing.
  • CANB has a Debt to Equity ratio of 1.00. This is in the lower half of the industry: CANB underperforms 76.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z 0.17
ROIC/WACC0.28
WACC5.78%
CANB.CA Yearly LT Debt VS Equity VS FCFCANB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

  • A Current Ratio of 1.33 indicates that CANB should not have too much problems paying its short term obligations.
  • CANB's Current ratio of 1.33 is on the low side compared to the rest of the industry. CANB is outperformed by 64.71% of its industry peers.
  • CANB has a Quick Ratio of 1.33. This is a bad value and indicates that CANB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • CANB has a Quick ratio of 0.27. This is amonst the worse of the industry: CANB underperforms 88.24% of its industry peers.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 0.27
CANB.CA Yearly Current Assets VS Current LiabilitesCANB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M

2

3. CANB.CA Growth Analysis

3.1 Past

  • CANB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -720.00%.
  • CANB shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -12.84%.
  • The Revenue has been growing by 30.72% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CANB.CA Yearly Revenue VS EstimatesCANB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

1

4. CANB.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • CANB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CANB.CA Price Earnings VS Forward Price EarningsCANB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • CANB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CANB is cheaper than 76.47% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.52
CANB.CA Per share dataCANB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. CANB.CA Dividend Analysis

5.1 Amount

  • CANB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

CANB.CA Fundamentals: All Metrics, Ratios and Statistics

CANADABIS CAPITAL INC

TSX-V:CANB (3/12/2026, 7:00:00 PM)

0.02

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-29
Earnings (Next)03-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners51.84%
Ins Owner ChangeN/A
Market Cap2.82M
Revenue(TTM)15.08M
Net Income(TTM)-1.29M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.19
P/FCF N/A
P/OCF N/A
P/B 0.37
P/tB 0.37
EV/EBITDA 7.52
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.11
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.26%
ROE -16.69%
ROCE 2.15%
ROIC 1.62%
ROICexc 1.73%
ROICexgc 1.73%
OM 1.9%
PM (TTM) N/A
GM 45.5%
FCFM N/A
ROA(3y)6.13%
ROA(5y)0.44%
ROE(3y)19.38%
ROE(5y)-14.57%
ROIC(3y)12.44%
ROIC(5y)N/A
ROICexc(3y)15.4%
ROICexc(5y)N/A
ROICexgc(3y)15.4%
ROICexgc(5y)N/A
ROCE(3y)15.95%
ROCE(5y)N/A
ROICexgc growth 3Y-38.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-38.64%
ROICexc growth 5YN/A
OM growth 3Y-28.69%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.68%
GM growth 5Y5.67%
F-Score1
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA 6.65
Cap/Depr 7.85%
Cap/Sales 0.46%
Interest Coverage 0.86
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 0.27
Altman-Z 0.17
F-Score1
WACC5.78%
ROIC/WACC0.28
Cap/Depr(3y)67.82%
Cap/Depr(5y)55.13%
Cap/Sales(3y)2.43%
Cap/Sales(5y)2.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-720%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-139.13%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-12.84%
Revenue growth 3Y13.14%
Revenue growth 5Y30.72%
Sales Q2Q%-35.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.84%
EBIT growth 3Y-19.31%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-161.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-147.44%
OCF growth 3YN/A
OCF growth 5YN/A

CANADABIS CAPITAL INC / CANB.CA FAQ

Can you provide the ChartMill fundamental rating for CANADABIS CAPITAL INC?

ChartMill assigns a fundamental rating of 2 / 10 to CANB.CA.


What is the valuation status of CANADABIS CAPITAL INC (CANB.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to CANADABIS CAPITAL INC (CANB.CA). This can be considered as Overvalued.


How profitable is CANADABIS CAPITAL INC (CANB.CA) stock?

CANADABIS CAPITAL INC (CANB.CA) has a profitability rating of 4 / 10.


Can you provide the financial health for CANB stock?

The financial health rating of CANADABIS CAPITAL INC (CANB.CA) is 1 / 10.